Once lauded for its clinical success, Roche casts off cardio program inclacumab for a mere $2M to Global Blood Therapeutics
Five years ago, Roche touted a clinical success for one of its mid-stage cardio programs, reporting the investigational med showed promise in reducing heart damage. Promising, they said, but apparently not promising enough. Roche quietly discontinued that program after Phase II trials and we didn’t hear about it again until today: Roche has sold it to a San Francisco biotech for a paltry $2 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.